Company intelligence / Profile preview

LiteVax BV

Ownership: Private
Development stage: Other

Overview

LiteVax BV develops novel human vaccine adjuvants that outperform current alternatives by providing higher efficacy with minimal toxicity. Their lead candidate enables lower-cost production and effective single-dose applications. The company’s main program has entered its second clinical trial as of February 2024, targeting improved influenza vaccination in the elderly population.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Vaccine adjuvants (synthetic carbohydrate and polymer-based)Nanofiber technology for transmucosal deliveryImmunogenic vaccines (e.g., HER2 vaccine)
Industry: Biotech

Drug pipeline

12 assets

TETRALITE

11 more assets in the full pipeline.

Partnerships

INDIGO consortium partners from EU, India, USAdaptVacExpreS^ion BiotechnologiesProxi BiotechCellVaxINRAEImmunoPrecise AntibodiesIRTAmultiple public/private R&D organizations via EU projects.

Beyond the preview

Go deeper on LiteVax BV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LiteVax BV.